New anticoagulants: beyond heparin, low‐molecular‐weight heparin and warfarin | Zendy

Bates Shan M | Zendy; Weitz Jeffrey I | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Premium

New anticoagulants: beyond heparin, low‐molecular‐weight heparin and warfarin

Author(s) -

Bates Shan M,

Weitz Jeffrey I

Publication year - 2005

Publication title -

british journal of pharmacology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.432

H-Index - 211

eISSN - 1476-5381

pISSN - 0007-1188

DOI - 10.1038/sj.bjp.0706153

Subject(s) - warfarin , heparin , anticoagulant , medicine , venous thromboembolism , intensive care medicine , low molecular weight heparin , pharmacology , thrombosis , atrial fibrillation

The limitations of traditional anticoagulants, heparin and warfarin, have prompted the development of new anticoagulant drugs for prevention and treatment of both venous and arterial thromboembolism. After a brief review of thrombogenesis and its regulation, this paper focuses on new anticoagulant agents in more advanced stages of clinical testing. British Journal of Pharmacology (2005) 144 , 1017–1028. doi: 10.1038/sj.bjp.0706153

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here

Accelerating Research